Rigel Pharmaceuticals (RIGL) Tops Q4 EPS by 1354c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $50.43 +3.21%
EPS Growth %: -34.9%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: -34.9%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q4 EPS of $13.54. Revenue for the quarter came in at $69.8 million.
For earnings history and earnings-related data on Rigel Pharmaceuticals (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- FingerMotion signs non-binding AI data center deal worth $100M+
- Intel shares fall as competitor reports record results
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
